SynthesisBMC infectious diseases2021
MPT64 assays for the rapid detection of Mycobacterium tuberculosis.
Synthesis in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Article
- Performance and Cost-Efficiency of an MPT64 Assay for DetectingJournal of Korean medical science · 2026Article
- Clinical management of XpertBMC infectious diseases · 2026Observational
- Immunoinformatic Design and Evaluation of a Multi-Epitope mRNA Vaccine RP14914P Targeting Latent Tuberculosis Infection.Pathogens (Basel, Switzerland) · 2026Article
- From immunoinformatics insights to assay development: establishment of a peptide-based indirect elisa for cynomolgus tuberculosis detection.Frontiers in cellular and infection microbiology · 2026Article
- Immunoinformatics analysis of the proteins MPT83 and MPT51 to design a possible chimeric vaccine against Mycobacterium tuberculosis.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Expression of a Tuberculosis-Associated Immunogenic Protein inLife (Basel, Switzerland) · 2025Article
- Article
- Epidemiology of drug-resistant tuberculosis among hospitalized children with tuberculosis in southwest China, 2017-2024.Frontiers in microbiology · 2025Article
- Immunogenicity and protective efficacy of a multi-antigenic adenovirus-based vaccine candidate againstFrontiers in microbiology · 2025Article
- The application of aptamer in tuberculosis diagnosis: a systematic review.Tropical diseases, travel medicine and vaccines · 2024Review
- Biochip-Based Identification of Mycobacterial Species in Russia.International journal of molecular sciences · 2024Article
- Immunohistochemistry and real-time Polymerase Chain Reaction: importance in the diagnosis of intestinal tuberculosis in a Peruvian population.BMC gastroenterology · 2024Observational
- Construction of novel multi-epitope-based diagnostic biomarker HP16118P and its application in the differential diagnosis of Mycobacterium tuberculosis latent infection.Molecular biomedicine · 2024Article
- Exploring the Potential of Exosomes as Biomarkers in Tuberculosis and Other Diseases.International journal of molecular sciences · 2024Review
- Synthesis of plant-based, self-adjuvanted, dual antigen specific to Mycobacterium tuberculosis as a novel tuberculosis subunit vaccine that elicits immunogenicity in rabbit.Biotechnology letters · 2023Article
- Detection ofPathogens (Basel, Switzerland) · 2023Article
- Osteoarticular tuberculosis cases in the southwest of China: A 9-year retrospective study.Frontiers in medicine · 2023Article
- Advancing proficiency testing for ultra in resource-limited settings using dried tube specimen: A study by SRL-Uganda.PloS one · 2023Article
- Epidemiology of Nontuberculous Mycobacteria in Tuberculosis suspects, Southwest of China, 2017-2022.Frontiers in cellular and infection microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTuberculosis (TB) is a serious infectious disease caused by Mycobacterium tuberculosis (MTB). An estimated 1.7 billion people worldwide are infected with Mycobacterium tuberculosis (LTBI) during the incubation period without any obvious symptoms. Because of MTB's high infection and mortality rates, there is an urgent need to develop a fast, portable, and sensitive diagnostic technology for its detection.
methodsWe included research from PubMed, Cochrane Library, Web of Science, and Embase and extracted the data. MetaDisc and STATA were used to build forest plots, Deek's funnel plot, Fagan plot, and bivariate boxplot for analysis.
resultsForty-six articles were analyzed, the results of which are as follows: sensitivity and specificity were 0.92 (0.91-0.93) and 0.95 (0.94-0.95) respectively. The NLR and PLR were 0.04 (95% CI 0.03-0.07) and 25.32 (95% CI 12.38-51.78) respectively. DOR was 639.60 (243.04-1683.18). The area under the SROC curve (AUC) was 0.99.
conclusionsMPT64 exhibits good diagnostic efficiency for MTB. There is no obvious heterogeneity between the three commercial kits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.